Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
Matthew R. Sydes(MRC Clinical Trials Unit at UCL), Nicholas D. James(Royal Marsden NHS Foundation Trust), Duncan B. McLaren(NHS Lothian), Robert Hughes(Mount Vernon Hospital), John M. Russell, Silke Gillessen(Institute of Oncology Research), Mahesh Parmar(University College London), Daniel Ford(Queen Elizabeth Hospital Birmingham), John Wagstaff(Maastricht University Medical Centre), Narayanan Srihari(Shrewsbury and Telford Hospital NHS Trust), David P. Dearnaley(Royal Marsden NHS Foundation Trust), Raeto T. Strebel(Swiss Group For Clinical Cancer Research), Malcolm D. Mason(Royal Marsden Hospital), William Cross(Leeds Teaching Hospitals NHS Trust), Claire Amos(MRC Clinical Trials Unit at UCL), Ananya Choudhury(University of Manchester), Clare Gilson(Cancer Research UK), Shaun Tolan(Clatterbridge Cancer Centre NHS Foundation Trust), Robert J. Jones(Beatson West of Scotland Cancer Centre), Joe M. O’Sullivan(San Antonio College), C. Peedell(South Tees Hospitals NHS Foundation Trust), Matthew Simms(Hull and East Yorkshire Hospitals NHS Trust), Joanna Gale(Queen Alexandra Hospital), Andrew Protheroe(University of Oxford), Omi Parikh(Royal Blackburn Teaching Hospital), Noel W. Clarke(The Christie NHS Foundation Trust), David Matheson(MRC Clinical Trials Unit at UCL), Johann S. de Bono(Royal Marsden NHS Foundation Trust), J.F. Lester(Cancer Research UK), Lisa Capaldi, Duncan C. Gilbert(Royal Sussex County Hospital), Richard Shaffer(Bupa Cromwell Hospital), Alison Birtle(University of Lancashire), Santhanam Sundar(Nottingham University Hospitals NHS Trust), Susannah Brock, Chris Parker(Royal Marsden NHS Foundation Trust), Sarah Maria Rudman(Guy's and St Thomas' NHS Foundation Trust), Denise Sheehan(Royal Devon and Exeter Hospital), Zafar Malik(Cancer Research UK), Melissa Spears(MRC Clinical Trials Unit at UCL), S. Chowdhury(Guy's and St Thomas' NHS Foundation Trust), A.W.S. Ritchie(MRC Clinical Trials Unit at UCL), Linda Evans(Weston Park Cancer Centre), D. Tsang(Southend Hospital), R. Millman(MRC Clinical Trials Unit at UCL), Stephanie Gibbs(Queen's Hospital), P. Chakraborti(Royal Derby Hospital), Ashok Nikapota(University Hospitals Sussex NHS Foundation Trust), M. Varughese(Musgrove Park Hospital), Gerhardt Attard(London Cancer)
Cited by 252
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k